Please login to the form below

Not currently logged in
Email:
Password:

GSK's Deborah Waterhouse to take over from ViiV' Dominique Limet

She will become CEO designate at the HIV-focused firm in January

ViiV Deborah WaterhouseGlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare's CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March.

Limet has served as ViiV's CEO since its 2009 formation as a partnership between GSK and Pfizer, with Shionogi subsequently joining the venture in 2012.

He said: “Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and extremely fulfilling personally. I have had the pleasure to work with an exceptional team and am proud of how the business has grown to its current position as a leader in HIV therapy.

“We have delivered scientific innovation, while listening and better understanding the needs of people living with HIV, allowing us to both do good and do well as a business.”

Waterhouse, who is currently senior VP of primary care within GSK's US pharmaceuticals business will take up a CEO designate role at ViiV in January, when she will be replaced by the company's VP of US primary care sales Cheryl MacDiarmid.

23rd December 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
inVentiv Health Communications

inVentiv Health Communications brings together best-in-class agencies across advertising, digital, public relations, medical communications, research, market access and clinical trial...

Latest intelligence

arrow
Patently unclear?
The challenge of protecting biotech innovations...
Waiting room
Patient recruitment and engagement standards
Clinical trial awareness...
Island
Adding value in emerging markets
What benefit do branded generics bring to patients around the world?...

Infographics